US Dollar Rises on Middle East Tensions as Markets Monitor Iran-US Negotiations 
Asian Stocks Climb as AI Optimism Boosts Tech Shares; South Korea Leads Gains 
Oil Prices Rebound Above $92 as Israel-Hezbollah Conflict Fuels Middle East Supply Concerns 
Trump, Syrian President Sharaa Discuss Sanctions Relief and Economic Recovery in Phone Call 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
Indian Government Bonds Seen Opening Steady Ahead of RBI Policy Decision 
Japan Weighs Two-Year Food Tax Cut Starting in 2027 to Ease Cost-of-Living Pressure 
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
Oil Prices Surge as Iran Suspends U.S. Talks Amid Middle East Tensions 
Asian Currencies Hold Steady as U.S. Dollar Gains on Inflation and Middle East Concerns 
Australia Minimum Wage to Rise 4.75% as Inflation Pressures Persist 
Jerome Powell Warns Against Politicizing the Federal Reserve, Defends Democratic Institutions 
US Stock Futures Slip as Iran Tensions Rise and AI-Fueled Tech Rally Loses Steam 
Trump Revises U.S. Tariffs on Copper, Aluminum, and Steel Imports Through 2027 
Kevin Warsh Faces Early Fed Test as Inflation Risks Challenge Rate-Cut Expectations 
Australia GDP Growth Faces Headwinds as Trade Deficit Widens and Imports Surge in Q1 2026 
Gold Prices Fall as Stronger Dollar and Iran Tensions Weigh on Market Sentiment 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
